Pro-Pharmaceuticals' strategy is to commercialize a new generation of cancer drugs, significantly upgrading their safety and efficacy over standard therapeutics. Key elements of our strategy are to:

• Focus exclusively on carbohydrate enhancement of chemotherapeutic agents
• Generate clinical data showing improved efficacy and/or lowered toxicity
• Pursue fast-track FDA regulatory approval for each drug we develop
• License our drugs via strategic partnerships or joint ventures

Drugs upgraded via our Glycoscience technology exhibit three major benefits:

REDUCED TOXICITY In animal studies, our drug technology protected healthy cells from the drug-induced destruction normally associated with chemotherapy regimens.

IMPROVED DRUG EFFICACY Ongoing research in animal trials suggest our glyco-upgrade drug technology may facilitate the delivery of chemotherapeutic agents to cancer cells. We are continuing these studies.

SHORT TIME TO MARKET Since the active agent in each drug is already FDA-approved, we anticipate dramatically reduced approval times for medications we develop.